ProCE Banner Activity

The Evolving Role of Immunotherapy in Advanced NSCLC

Slideset Download
Download these slides from a live CCO Webinar for an overview of the evolving immunotherapy landscape for advanced or metastatic NSCLC, including for special populations.

Released: September 17, 2021

Expiration: September 16, 2022

No longer available for credit.

Share

Faculty

Julie Brahmer

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Jarushka Naidoo

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Genentech, a member of the Roche Group

Helsinn Healthcare SA

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Julie Brahmer, MD

Associate Professor of Oncology
Oncology/Upper Aerodigestive Cancer Program
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

Julie Brahmer, MD, MSc, FASCO, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Eli Lilly, GlaxoSmithKline, Merck, Regeneron and Sanofi; funds for research support from AstraZeneca, Bristol-Myers Squibb, Genentech/Roche, Merck, RAPT Therapeutics and Revolution Medicines; and fees for non-CME/CE services (eg, DSMB) from GlaxoSmithKline, Janssen and Sanofi.

Jarushka Naidoo, MB BCH BAO, MHS

Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Professor of Oncology
Sidney Kimmel Comprehensive
Johns Hopkins University
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS, has disclosed that she has received consulting fees from AstraZeneca, Daiichi Sankyo, Merck, Pfizer, Roche/Genentech, and Takeda and funds for research support from AstraZeneca and Merck.